Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease

被引：0
|
作者：
Attara, G. [1 ]
Bailey, R. [2 ]
Bressler, B. [3 ]
Marshall, J. [4 ]
Panaccione, R. [5 ]
Aumais, G. [6 ]
机构：
[1] Gastrointestinal Soc, Vancouver, BC, Canada
[2] Univ Alberta, Dept Med, Zeidler Ledcor Ctr, Div Gastroenterol, Edmonton, AB, Canada
[3] Univ British Columbia, St Pauls Hosp, Div Gastroenterol, Med, Vancouver, BC V5Z 1M9, Canada
[4] McMaster Univ, Med Ctr, Dept Gastroenterol, Hamilton, ON, Canada
[5] Univ Calgary, Foothills Med Ctr, Dept Gastroenterol, Calgary, AB, Canada
[6] CHUM, Hop Maisonneuve Rosemont, Med, Montreal, PQ, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P433
引用
收藏
页码：S319 / S319
页数：1
相关论文
共 50 条
  • [1] Canadian Patient and Caregiver Perspectives on Subsequent Entry Biologics/Biosimilars for Inflammatory Bowel Disease
    Attara, Gail
    Bressler, Brian
    Bailey, Robert
    Marshall, John. K.
    Panaccione, Remo
    Aumais, Guy
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S443 - S444
  • [2] Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics
    Devlin, Shane M.
    Bressler, Brian
    Bernstein, Charles N.
    Fedorak, Richard N.
    Bitton, Alain
    Singh, Harminder
    Feagan, Brian G.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 27 (10): : 567 - 571
  • [3] CANADIAN PUBLIC REIMBURSEMENT OF SUBSEQUENT ENTRY BIOLOGICS (SEBS) / BIOSIMILARS
    Siu, E. C.
    Wyatt, G.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A168 - A168
  • [4] Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists
    Grabowski, David
    Henderson, Bradley
    Lam, Dennis
    Keystone, Edward C.
    Thorne, Carter
    Jamal, Shahin
    Pope, Janet
    Haraoui, Boulos
    Lin, Daming
    Revers, Leigh
    [J]. CLINICAL RHEUMATOLOGY, 2015, 34 (08) : 1427 - 1433
  • [5] Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists
    David Grabowski
    Bradley Henderson
    Dennis Lam
    Edward C. Keystone
    Carter Thorne
    Shahin Jamal
    Janet Pope
    Boulos Haraoui
    Daming Lin
    Leigh Revers
    [J]. Clinical Rheumatology, 2015, 34 : 1427 - 1433
  • [6] Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
    Rawla, Prashanth
    Sunkara, Tagore
    Raj, Jeffrey Pradeep
    [J]. JOURNAL OF INFLAMMATION RESEARCH, 2018, 11 : 215 - 226
  • [7] Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease
    Raffals, Laura E.
    Nguyen, Geoffrey C.
    Rubin, David T.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (05) : 818 - 823
  • [8] CANADIAN PUBLIC REIMBURSEMENT OF BIOSIMILARS (REFERRED TO AS SUBSEQUENT ENTRY BIOLOGICS -SEBS - IN CANADA), AN UPDATE
    Siu, E. C.
    Wyatt, G.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
  • [9] Current state of subsequent entry biologics (biosimilars) in Canada: a view from regulatory, reimbursement, clinician, and patient perspectives
    Siu, Eric C. K.
    Wyatt, George
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2016, 5 (03): : 105 - 113
  • [10] Subsequent entry biologics/biosimilars: a viewpoint from Canada
    Russell, Anthony S.
    Ahluwalla, Vandana
    Barnabe, Cheryl
    Jamal, Shahin
    Offer, Robert C.
    Olszynski, Wojciech P.
    Shojania, Kam
    Haraoui, Boulos
    [J]. CLINICAL RHEUMATOLOGY, 2012, 31 (09) : 1289 - 1292
12345